Unlock instant, AI-driven research and patent intelligence for your innovation.

Application of CDHR3 as tumor diagnostic marker

A technology for osteosarcoma and biological samples, applied in the application field of CDHR3 agonist in the treatment of osteosarcoma, can solve the problems of few molecular markers, under-researched, low incidence of osteosarcoma, etc., and achieve fast and accurate quantification. , good application prospect, high sensitivity effect

Inactive Publication Date: 2017-07-04
BEIJING MEDINTELL BIOMED CO LTD
View PDF0 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, due to the low incidence of osteosarcoma, about 0.3 / 10,000, it is difficult to collect samples and has not been studied in depth. Currently, there are not many molecular markers for osteosarcoma

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of CDHR3 as tumor diagnostic marker
  • Application of CDHR3 as tumor diagnostic marker
  • Application of CDHR3 as tumor diagnostic marker

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0039] Example 1 High-throughput sequencing and analysis

[0040] 10 samples of osteosarcoma cases and 5 cases of normal control tissues were collected, among which 5 were primary samples and 5 were metastatic samples in the 10 cases of osteosarcoma. Perform RNA extraction and agarose gel electrophoresis after RNA extraction. From the electrophoresis results, it can be preliminarily judged whether the quality of the extracted RNA sample is qualified or not, and whether it can be used for further transcriptome analysis. Then, the extraction of RNA samples was detected by NanoDrop1000 spectrophotometer, and the sample requirements for RNA-seq sequencing: OD260 / OD280 was 1.8-2.2.

[0041] The sequencing platform is the HiSeq 2500 high-throughput sequencing platform of Illumina, which performs high-throughput transcriptome deep sequencing. After sequencing, we use Fast-QC software to evaluate the quality of the sequencing data as a whole, including the quality value distribution o...

Embodiment 2

[0042] Example 2 Osteosarcoma group and normal group CDHR3 gene expression

[0043] 1. Materials and methods

[0044] 1. Materials

[0045] 17 osteosarcoma tissue samples, 28 osteosarcoma blood samples, 6 normal bone tissue controls, and 20 normal blood samples were collected, grouped and numbered.

[0046] Tissue extraction: During the patient's first operation, tissue samples were extracted during the operation under aseptic operation, and each piece was cut into the size of soybeans. After taking it out, it was quickly put into a cryopreservation tube, and placed in liquid nitrogen as soon as possible.

[0047] Blood extraction: After the patient is confirmed, collect 3-5 ml of peripheral blood samples in time, put them into EDTA anticoagulant tubes quickly, and place them in a -80°C refrigerator as soon as possible.

[0048] 2. Method

[0049] 2.1 Extraction of osteosarcoma and normal control total RNA

[0050] use Reagent (invitrogen, Cat. No. 15596-018) was used to...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates to an application of CDHR3 as a tumor diagnostic marker, and more specifically, relates to the CDHR3 as an osteosarcoma diagnostic marker and an application of the CDHR3 agonist in treatment of osteosarcoma. Osteosarcoma is not studied intensively because of low incidence rate, and not many osteosarcoma molecular markers exist at present. High throughput sequencing of osteosarcoma case samples is performed, bioinformatics analysis and molecular biology experiments are combined, and the gene CDHR3 closely associated with osteosarcoma is selected, is expected to become the osteosarcoma diagnostic marker, provides a reference for clinical diagnosis, and provides clinical basis for early diagnosis of osteosarcoma.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the application of CDHR3 as a tumor diagnostic marker, and more specifically to the application of CDHR3 as a diagnostic marker of osteosarcoma and the application of CDHR3 agonists in the treatment of osteosarcoma. Background technique [0002] The CDHR3 gene is located in the 7q22.3 region of the chromosome. It is a transmembrane protein containing six outer cadherin domains. It can mediate the adhesion of homologous cells and participate in cell differentiation and cell-cell interaction. A gene that has been shown to play an important role in the development of very early asthma, but has not been reported to be associated with osteosarcoma. [0003] Osteosarcoma is a primary malignant bone tumor originating from bone mesenchymal cells. The age of onset is mostly 8-25 years old. It is extremely harmful to society. Its hematogenous metastasis occurs early and has a high incidence and ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): C12Q1/68G01N33/68G01N33/574A61K45/00A61P35/00
CPCC12Q1/6886A61K45/00C12Q2600/158G01N33/57407G01N33/68G01N2800/10
Inventor 杨承刚任静向常娟
Owner BEIJING MEDINTELL BIOMED CO LTD